EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Farnesoid X Receptor Agonist Tropifexor Improves Intestinal Defense Response and Epithelial Barrier Function in Neonatal Piglets Receiving Parenteral Nutrition

Yuling Zhao, Yongtao Xiao, Lu Jiang iD, Ying Wang iD, Yang Liu, Tian Zhang iD, Wei Cai, Junkai Yan

The FASEB Journal · 15.10.2025 · 39 (19)

DOI: 10.1096/fj.202502233r ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 07.10.2025. Verfasst von Yuling Zhao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Hauptthemen laut MEDLINE: Receptors, Cytoplasmic and Nuclear, Intestinal Mucosa, Parenteral Nutrition. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MOST | National Natural Science Foundation of China (NSFC), Shanghai Science and Technology Innovation Action Plan, Shanghai Municipal Health Commission ().

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Long‐term parenteral nutrition (PN) can lead to liver and intestinal injury in neonates, but effective prevention strategies are limited. Our previous research demonstrated that activation of farnesoid X receptor (FXR) signaling with tropifexor (TXR) could mitigate PN‐induced liver damage in neonatal piglets, but its effect on intestinal injury remains to be addressed. In this study, two‐day‐old Bama minipigs were randomly allocated into three groups ( n = 6/group): EN (receiving enteral nutrition, serving as a control), PN, and PT (PN + TXR treatment). Consequently, TXR treatment significantly mitigated PN‐induced intestinal injury, including villus atrophy, hyper‐permeability, and impaired defense responses. Transcriptomic profiling identified 1188 differentially expressed genes (DEGs) in the PN group compared to EN, among which 108 genes could be substantially attenuated by TXR. Notably, bioinformatics analysis suggested that these DEGs could be classified into “positive regulation of defense response” and “cell–cell adhesion”. Moreover, the top 25 hub genes were identified, including EPCAM, CD28, and IFNG. Furthermore, we demonstrated that EPCAM decreased significantly upon PN administration, which could be substantially attenuated by TXR. Finally, in order to further validate the role of TXR in modulating intestinal barrier function, patient‐derived organoids (PDOs) were used as a mini‐gut model in vitro. Consequently, pharmacological activation of FXR by TXR substantially induced EPCAM expression and enhanced epithelial barrier integrity, particularly in the PDOs derived from pediatric patients receiving PN, while no significant changes were found in those derived from patients receiving oral feeding. In conclusion, this study suggested that TXR treatment could alleviate PN‐induced impairment of defense responses and epithelial barrier dysfunction, potentially offering a preventive strategy for neonates receiving long‐term PN therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Cytoplasmic and NuclearIntestinal MucosaParenteral NutritionAnimalsSwineAnimals, NewbornSwine, MiniatureTranscriptomeReceptor, Farnesoid X-Activated

Stichwörter der Autor:innen

farnesoid X receptorintestinal barrier functionparenteral nutritionpatient‐derived organoidstropifexor

Substanzen

Receptors, Cytoplasmic and NuclearReceptor, Farnesoid X-Activated

Autor:innen und Institutionen

  • Department of Pediatric Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Division of Pediatric Gastroenterology and Nutrition, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Shanghai Institute for Pediatric Research, Shanghai, China.
  • Shanghai Key Laboratory of Pediatric Gastroenterology and Nutrition, Shanghai, China.

ORCID-Profile: Lu Jiang, Ying Wang, Tian Zhang

Förderung

  • MOST | National Natural Science Foundation of China (NSFC)
  • Shanghai Science and Technology Innovation Action Plan
  • Shanghai Municipal Health Commission ()
  • National Natural Science Foundation of China

Zitieren

APA

Zhao, Y., Xiao, Y., Jiang, L., Wang, Y., Liu, Y., Zhang, T., Cai, W., & Yan, J. (2025). Farnesoid X Receptor Agonist Tropifexor Improves Intestinal Defense Response and Epithelial Barrier Function in Neonatal Piglets Receiving Parenteral Nutrition. The FASEB Journal, 39(19). https://doi.org/10.1096/fj.202502233r

Vancouver

Zhao Y, Xiao Y, Jiang L, Wang Y, Liu Y, Zhang T, et al. Farnesoid X Receptor Agonist Tropifexor Improves Intestinal Defense Response and Epithelial Barrier Function in Neonatal Piglets Receiving Parenteral Nutrition. The FASEB Journal. 2025;39(19). doi:10.1096/fj.202502233r

BibTeX
@article{Zhao2025,
  author = {Zhao, Yuling and Xiao, Yongtao and Jiang, Lu and Wang, Ying and Liu, Yang and Zhang, Tian and Cai, Wei and Yan, Junkai},
  title = {Farnesoid X Receptor Agonist Tropifexor Improves Intestinal Defense Response and Epithelial Barrier Function in Neonatal Piglets Receiving Parenteral Nutrition},
  journal = {The FASEB Journal},
  year = {2025},
  volume = {39},
  number = {19},
  doi = {10.1096/fj.202502233r}
}
Kostenlos starten →